Pelican-Cancer-Foundation-logos
Donate Now
Search
Pelican-Cancer-Foundation-logos

Dedicated to helping patients with bowel and liver cancer live well for longer

Donate Now
Search
  • Home
  • About us
    • About us
    • What we do
      • Our achievements
      • The Future
    • Who we are
      • Trustees
      • Our Team
      • Patrons
      • Annual Accounts
    • Partnerships
    • Vacancies
    • News
  • Education
    • Pelican OReCO
      • OReCO On-line Resources
      • OReCO Partners & Sponsors
      • Pelican OReCO Workshops
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
    • LARS
    • Sponsors
      • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Films
  • Research
    • MERCURY 3
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Previous Research Areas
      • Prostate Cancer Research
        • Prostate cancer
        • Focal therapy and HIFU research
        • MRI research for prostate cancer
        • Prostate cancer colloquiums
        • FORECAST
        • Trachtomap
        • Papers of interest
      • Bladder cancer research
        • Bladder cancer
        • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for research applicants
      • Peer Review Panel Terms of Reference
      • Research Review Panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Pseudomyxoma peritonei
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Shares
      • In memory
    • Fundraise for us
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
    • Leave a Gift in your Will
    • Become a Corporate Partner
    • Trusts, Foundations & Philanthropy
    • Tell us your story
  • Contact us

MERCURY 2 (Low Rectal Cancer Study)

Treatment of cancer of the rectum has improved in the past decade. However low rectal cancers (those within 6 cm of the end of the anus), treated with removal of the bowel and the anus (Abdomino-Perineal Excision, APE) continue to have poor outcome, with a positive margin (where some cancer is left behind) occurring in around 30% of patients. Low rectal cancer occurs in about 5,000 patients per year in the UK, so any improvement in the treatment of these tumours would have a substantial benefit.

Depending on how far the tumour has spread beyond the bowel wall will determine whether a patient can have an operation to rejoin the bowel, preserving bowel function (low anterior resection – LAR) or whether they will require an APE. It will also determine whether they will require chemo- and radiotherapy prior to their operation.

To view videos of APE click here.

This nationwide study aims to assess the accuracy of Magnetic Resonance Imaging (MRI scanning) in accurately predicting how far the tumours have spread. Results will show how safely and effectively this information can be used to allow the tailoring of surgery (either LAR or CYLINDRICAL APE) and pre-operative chemo- and radiotherapy. After the operation we will monitor the quality of life experienced by these patients to allow us to aid decision-making for patients and the medical community.

Pelican seeks to optimise surgical techniques and therapy choices for the future. We believe that if clinical assessment prior to treatment is as informed and accurate as possible, then the best therapies and surgical options can be applied, resulting in the best possible outcome.

If you are a centre interested in participating in the MERCURY 2 Study (Low Rectal Cancer Study) please contact Pelican on +44 1256 314746 or at admin@pelicancancer.org or Professor Gina Brown at gina.brown@rmh.nhs.uk .

For investigators:

A number of pdf documents can be downloaded for this study:

  • GP Invitation Letter
  • Patient Invitation Letter
  • Low Rectal Cancer Study Summary
  • Protocol Version 2.6
  • Completion of Treatment Form
  • Longterm Follow Up Form

Datasheets:

  • Clinical Assessment and Registration
  • Patient MRI Datasheet
  • MDT Decision Form
  • Operation Datasheet
  • 30 Day Morbidity and Mortality Form
  • Pathology Reporting Form
  • QOL Questionnaire
  • Patient Pack

For trial participants (patients):

Patient information sheet

Patients are invited to take part in a research study. Before a final decision it is important to understand why the research is being done and what it will involve.

  • Part 1 outlines the purpose of this study and what will happen if a patient takes part.
  • Part 2 gives more detailed information about the conduct of the study.

Please ask us if there is anything that is not clear, or if you would like more information.

Part 1

If the information in Part 1 has interested you and you are considering participation, please continue to read the additional information in Part 2 before making any decision.

Part 2

You will be given a copy of the information sheet and a signed consent form to keep. Thank you very much for reading this, and for considering taking part in our study.

Stay in touch

Sign up to hear from us
Donate Now

© 2023 Pelican Cancer Foundation - all rights reserved

  Registered Charity Number: 1141911 -  Privacy Policy